A novel strategy for the synthesis of 6*H*-chromeno [4, 3-*b*] quinoline by intramolecular Heck cyclization

Morteza Shiri ^{a,*}, Mina Fathollahi-Lahroud ^a and Zahra Yasaei ^a

^a Department of Chemistry, Faculty of Physics and Chemistry, Alzahra University, Vanak, Tehran 1993893973, Iran, E-mail: mshiri@alzahra.ac.ir

ARTICLE INFO

Article history:

Received

Received in revised form

Accepted

Available online

Keywords:

Intramolecular Heck Reaction;
 6*H*-chromeno [4,3-*b*] quinolines;
 Palladium;
 Indole.

ABSTRACT

A novel procedure for the synthesis of various derivatives of 6*H*-chromeno [4, 3-*b*] quinolines from intramolecular Heck reaction of 2-chloro-3-(phenoxymethyl) quinolines is described in this study. Interamolecular cyclisation of *N*-alkylated indoles was efficiently investigated as well. The reaction is catalyzed by bis (triphenylphosphine) palladium (II) dichloride in acetonitrile at 80 °C.

2009 Elsevier Ltd. All rights reserved.

1. Introduction

An understanding of the details of C-C bond formation of organometallic reactions, has persuaded chemists to use this strong key step in pharmaceutical and total synthesis of natural products. The precise choice of Pd catalyst and base will give arylation and vinylation of alkenes in a Heck procedure.¹ Intramolecular Heck reaction is a straightforward approach to the synthesis of pharmaceuticals² heterocycles and in total synthesis³, because very sterically hindered C-C bond forming in mild conditions is possible.⁴ To the best of our knowledge, aryl chlorides are not generally very reactive reagents in Heck coupling reactions; however, by installing electron-accepting substitutions they become useful counterparts.⁵ It should be noted that Pd catalyzed intramolecular C-H arylation in order to obtain fused dibenzo; 1, 6-naphthyridines has recently been reported.⁶

In accordance with the importance of activation of C-X bonds by intramolecular Heck procedure, quinolines and heteroaromatic compounds contain the moiety of significant frameworks, and they are a part of biological synthetic drugs or natural products.⁷ For example, three of the promising drugs of antimalarial depend on quinolines derivatives.⁸ Moreover, there are several reports of 6*H*-chromeno [4, 3-*b*] quinolines as estrogen receptor beta-selective ligands⁹, anti-inflammatory and Ulcerogenic activities.¹⁰

Recently, 6*H*-chromeno [4, 3-*b*] quinolines **2** skeleton have been synthesized by different research groups. Among them¹¹ are aza-Diels–Alder intramolecular Cu-catalyzed reaction¹² and copper-catalyzed reaction of arylpropynyloxy-benzonitriles with diaryliodonium triflates as arylating agent¹³ (Scheme 1). In continuation of our interest in chemistry of structures with quinoline core,¹⁴ we designed to prepare 6*H*-chromeno [4, 3-*b*]

quinoline by the activation of C-Cl bond of **1** in an intramolecular Heck coupling (Scheme 1).

Scheme 1

2. Results and discussion

The research started by preparing the starting material of 2-chloro-3-[(naphthalen-1-yloxy)methyl] quinoline **1a** by the previous reported procedures.¹⁵ In this way, to a solution of **1a** in acetonitrile, a palladium source of bis (triphenylphosphine) palladium (II) dichloride and K₂CO₃ as the base was added at 80 °C. After 24 h the desired 6*H*-chromeno [4, 3-*b*] quinoline **2a** obtained the major product (Table 1, entry 5). Then, the effect of various solvents, bases, ligands and catalysts in the reaction yield and time were explored (Table 1). By using acetone and toluene

the yield was very low, but by using aprotic polar solvents such as DMF and DMA the product **2a** was obtained in 70 and 85% yield respectively (Table 1, entries 1-4). By lowering the catalyst loading, the yield was decreased as well (Table 1, entries 5-8). Using other bases such as *t*-BuONa, NaHCO₃, NaOH and Cs₂CO₃ have not noticeable effect on the yield of product. With Et₃N the reaction did not progress at all. Potassium carbonate was chosen as the best base. Next, various source of palladium catalyst such as PdCl₂, Pd(OAc)₂, Pd(PPh₃)₄ were checked and the yields were 40%, 80% and 0% respectively. The crucial role of palladium in the formation of the product when omitting the catalyst, even with strong bases of KOH, *t*-BuOK and Cs₂CO₃ resulted without the desired product.

Table 1- Optimization of the reaction condition for the synthesis of 6*H*-chromeno [4, 3-*b*] quinoline **2a** from **1a**^a

Entr	Solvent	Base	Catalyst (10 mol%)	Ligand	Yield(%) ^b
1	Acetone	K ₂ CO ₃	PdCl ₂ (PPh ₃) ₂	-	20
2	Toluene	K ₂ CO ₃	PdCl ₂ (PPh ₃) ₂	-	42
3	DMF	K ₂ CO ₃	PdCl ₂ (PPh ₃) ₂	-	70
4	DMA	K ₂ CO ₃	PdCl ₂ (PPh ₃) ₂	-	84
5	CH ₃ CN	K ₂ CO ₃	PdCl ₂ (PPh ₃) ₂	-	90
6	CH ₃ CN	K ₂ CO ₃	PdCl ₂ (PPh ₃) ₂ (8%)	-	81
7	CH ₃ CN	K ₂ CO ₃	PdCl ₂ (PPh ₃) ₂ (5%)	-	43
8	CH ₃ CN	K ₂ CO ₃	PdCl ₂ (PPh ₃) ₂ (2%)	-	Trace
9	CH ₃ CN	NaOAc	PdCl ₂ (PPh ₃) ₂	-	N.R

^a **1a** (1 mmol), Cat. (10 mol%), Base (2 mmol), Solvent (5 mL), reflux, 24 h

^b Isolated yields

The optimized reaction condition, Pd(PPh₃)₂Cl₂ (10 mol%) as catalyst, K₂CO₃ as the base, reflux of CH₃CN, reaction time of 24 h, was examined on the generality of the reaction (Table 2).

As is clear from Table 2, electron-withdrawing and electron-donating groups on the both sides of ether **1** participated properly in the intramolecular cyclisation towards four and five membered azaheterocycles. Furthermore, tertiary butyl, as a good candidate of hindered groups, worked well to give **2g** in 70% yield (Table 2).

Next, for further exploration of the scope of the reaction, 3-[(1*H*-indol-1-yl) methyl]-2-chloroquinoline **3a** and 2-chloro-3-[(5-chloro-1*H*-indol-1-yl) methyl] quinoline **3b** were prepared (Scheme 2). The synthesis of five cycle indolo quinolines **4a** and **4b** were also facilitated by this method as demonstrated in Scheme 2.

Scheme 2

¹H-NMR spectra of **2a** and **2b** have some interesting information about the 3D-properties of the synthesized molecules. The indicated proton in **2a** (Fig. 1) which is deshielded aromatic proton, appeared as a doublet in chemical shift of 8.64. While such a proton in **2b** appeared as a doublet in 9.99 ppm. This is due to the proximity of the hydrogen to the electronegative nitrogen of quinoline ring as well as anisotropic effect.

Figure 1.

Table 2. Synthesis of various 6*H*-chromeno [4,3-*b*] quinolines **2a-n**

Product	R ¹	R ²	R ³	Yield(%) ^b
2				
c	H	H	H	83
d	H	H	Cl	88
e	H	H	F	90
f	H	H	CN	95
g	H	H	-C(CH ₃) ₃	70
h	H	Me	H	80
i	Br	H	H	77
j	Cl	H	CN	80
k	Me	H	CN	95
l	Me	H	F	92

2a (90%)

2b (95%)

^a Reaction condition: **1** (1 mmol), Pd(PPh₃)₂Cl₂ (10 mol%), K₂CO₃ (2 mmol) in CH₃CN (5 mL) at 80 °C for 24 h.

^b Isolated yields

A possible reaction mechanism is proposed for the formation of the product **2** (Scheme 3). Oxidative insertion of Pd into C-Cl bond of **1** makes intermediate (I). Deprotonation and intramolecular electrophilic substitution of the aromatic ring with loss of chloride gave a seven-membered palladacycle (II). The latter by reductively elimination of Pd(0) resulted the observed product **2**.

Scheme 3. The plausible mechanism of the reaction

3. Conclusions

In summary, a number of 6*H*-chromeno [4, 3-*b*] quinolines in a convenient and simple intramolecular cyclization were synthesized. 2-Chloro-3- (aryloxymethyl) quinolines were the starting materials which in front of 10 mol% of a palladium catalyst and K₂CO₃ in acetonitrile afforded the desired scaffolds. Aryl chlorides are rare starting reagents in Heck coupling procedures because they are considered unreactive in comparison to aryl bromides and iodides. The conjugates of important quinoline pharmacophore with chromen ring would be interesting in terms of its biological effects. Moreover, the reaction has the advantage of tolerance of a wide range of functional groups.

4. Experimental section

General

The chemicals were purchased from Fluka, Merck and Aldrich chemical companies. Melting points are uncorrected. IR spectra were recorded on a Shimadzu Infra-Red Spectroscopy IR-435. Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker Avance 400 MHz Spectrometer in CDCl₃ as a solvent. The elemental analysis was carried out with a Leco CHNS model 932. Mass spectra were recorded on Agilent Technology (HP) 5973 Network Mass Selective Detector operating at an ionization potential of 70 eV.

*The typical procedure for the synthesis of 6H-benzo [7, 8] chromeno [4, 3-*b*] quinolone (2a).* To a stirring solution of 2-chloro-3-[(naphthalen-1-yloxy) methyl] quinoline **4a** (1 mmol) in acetonitrile (5 mL), 10mol% of bis (triphenylphosphine) palladium (II) dichloride and potassium carbonate (2 mmol) were added. The reaction stirred at reflux condition for 24 h. The completion of the reaction was monitored by TLC. By filtration of the crude reaction and the evaporation of its solvent, the product was purified by a column chromatography (*n*-hexan: ethyl acetate 9:1).

Supplementary Material

6H-Benzo [7, 8]chromeno [4,3-*b*]quinoline (2a). Colorless needle crystal mp: 139-141 °C (from MeOH). ¹H-NMR (400 MHz, CDCl₃): δ = 5.60 (s, 2H), 7.51-7.60 (m, 3H), 7.65 (d, *J* = 8.4 Hz, 1H), 7.73 (t, *J* = 7.6 Hz, 1H), 7.84 (d, *J* = 8.6 Hz, 1H),

7.88 (d, *J* = 7.2 Hz, 1H), 7.94 (s, 1H), 8.19 (d, *J* = 8.4 Hz, 1H), 8.33 (d, *J* = 7.0 Hz, 1H), 8.59 (d, *J* = 8.4 Hz, 1H) ppm. ¹³C-NMR (100 MHz, CDCl₃): δ = 68.9, 117.6, 121.9, 122.1, 122.4, 124.8, 125.1, 125.8, 126.1, 127.4, 127.5, 127.6, 127.8, 129.4, 129.5, 130.7, 135.8, 148.5, 149.5, 153.9 ppm. Mass: *m/z* 283 (M⁺) (calcd for C₂₀H₁₃NO: 283.32). FT-IR (KBr): ν_{max}: 1100 (m), 1260 (m), 1571 (s), 2851 (m), 3061 (s) cm⁻¹. Analytically calculated for C₂₀H₁₃NO: C 84.78, H 4.62, N, 4.94%. Found: C 84.55; H 4.51; N 4.72%.

8H-Benzo [5, 6]chromeno [4,3-*b*]quinoline (2b). Colorless needle crystal, mp: 127-130 °C (from MeOH). ¹H-NMR (400 MHz, CDCl₃): δ = 5.36 (s, 2H), 7.27 (d, *J* = 8.8 Hz, 1H), 7.51 (t, *J* = 7.6 Hz, 1H), 7.56 (t, *J* = 8.0 Hz, 1H), 7.70 – 7.78 (m, 2H), 7.84 – 7.91 (m, 3H), 8.01 (s, 1H), 8.26 (d, *J* = 8.4 Hz, 1H), 9.99 (d, *J* = 8.8 Hz, 1H) ppm. ¹³C-NMR (100 MHz, CDCl₃): δ = 68.9, 116.2, 118.3, 121.6, 124.5, 126.3, 126.7, 127.1, 127.2, 127.9, 128.4, 129.4, 129.6, 130.7, 130.8, 131.3, 133.0, 148.0, 150.8, 157.8 ppm. Mass: *m/z* 283 (M⁺) (calcd for C₂₀H₁₃NO: 283.32).FT-IR (KBr): ν_{max}: 1100 (s), 1260 (s), 1742 (m), 2962 (w) cm⁻¹. Analytically calculated for C₂₀H₁₃NO: C 84.78, H 4.62, N, 4.94%. Found: C 84.61; H 4.33; N 4.79%.

6H-Chromeno [4, 3-*b*] quinoline (2c). Colorless needle crystal, mp: 85-89 °C (from MeOH). ¹H-NMR (400 MHz, CDCl₃): δ = 5.39 (s, 2H), 7.06 (d, *J* = 8.4 Hz, 1H), 7.21 (t, *J* = 8.0 Hz, 1H), 7.41 (t, *J* = 8.0 Hz, 1H), 7.52 (t, *J* = 7.6 Hz, 1H), 7.73 (t, *J* = 7.6 Hz, 1H), 7.80 (d, *J* = 8.4 Hz, 1H), 7.89 (s, 1H), 8.17 (d, *J* = 8.4 Hz, 1H), 8.53 (dd *J* = 7.6 Hz, *J* = 1.6 Hz, 1H) ppm. ¹³C-NMR (100 MHz, CDCl₃): δ = 68.4, 117.3, 122.6, 123.2, 125.2, 125.6, 126.3, 127.4, 127.6, 129.4, 129.5, 130.9, 131.9, 148.3, 149.3, 157.4 ppm. Mass: *m/z* 232 (M-1) (calcd for C₁₆H₁₁NO: 233.28). FT-IR (KBr): ν_{max}: 1017 (s), 1238 (m), 1605 (m), 2900 (w) cm⁻¹. Analytically calculated for C₁₆H₁₁NO: C 82.38, H 4.75, N, 6.00%. Found: C 82.19; H 4.59; N 6.12%.

2-Chloro-6H-chromeno [4, 3-*b*] quinoline (2d). Yellow needle crystal, mp: 113-117 °C (from MeOH). ¹H-NMR (400 MHz, CDCl₃): δ = 5.38 (d, *J* = 1.2 Hz, 2H), 6.98 (d, *J* = 8.8 Hz, 1H), 7.33 (dd, *J* = 8.8 Hz, *J* = 2.8 Hz, 1H), 7.55 (t, *J* = 8.8 Hz, 1H), 7.74 (t, *J* = 8.0 Hz, 1H), 7.80 (d, *J* = 8.4 Hz, 1H), 7.91 (s, 1H), 8.17 (d, *J* = 8.4 Hz, 1H), 8.49 (d, *J* = 2.8 Hz, 1H) ppm. ¹³C-NMR (100 MHz, CDCl₃): δ = 68.3, 118.6, 120.9, 124.8, 125.5, 126.9, 127.5, 127.8, 129.4, 129.6, 132.2, 133.7, 141.2, 151.0, 151.0, 155.9 ppm. Mass: *m/z* 266 (M-1) (calcd for C₁₆H₁₀ClNO: 267.05). FT-IR (KBr): ν_{max}: 736 (m), 1081 (m), 1242 (m), 3044 (w) cm⁻¹. Analytically calculated for C₁₆H₁₀ClNO: C 71.78, H 3.77, N, 5.23%. Found: C 71.53; H 3.81; N 5.19%.

2-Fluoro-6H-chromeno [4, 3-*b*] quinoline (2e). Yellow needle crystal, mp: 97-100 °C (from MeOH). ¹H-NMR (400 MHz, CDCl₃): δ = 5.37 (d, *J* = 0.8 Hz, 2H), 6.99-7.03 (m, 1H), 7.09 (dd, *J* = 8.0 Hz, *J* = 3.2 Hz, 1H), 7.55 (t, *J* = 6.8 Hz, 1H), 7.74 (t, *J* = 6.4 Hz, 1H), 7.81 (d, *J* = 8.4 Hz, 1H), 7.92 (s, 1H), 7.16 (d, *J* = 9.2 Hz, 1H), 8.19 (dd, *J* = 9.2 Hz, *J* = 3.2 Hz, 1H) ppm. ¹³C-NMR (100 MHz, CDCl₃): δ = 68.5, 118.5, 118.6, 122.2, 125.0, 126.7, 127.1, 127.7, 129.5, 129.8, 131.1, 148.2, 153.4, 157.2, 159.6 ppm. Mass: *m/z* 251 (M⁺) (calcd for C₁₆H₁₀FNO: 251.07). FT-IR (KBr): ν_{max}: 806 (m), 1113 (m), 1188 (m), 3046 (w) cm⁻¹. Analytically calculated for C₁₆H₁₀FNO: C 76.48, H 4.01, F 7.56, N, 5.57%. Found: C 76.18; H 4.18; N 5.31%.

6H-Chromeno [4, 3-*b*] quinoline-2-carbonitrile (2f). Yellow needle crystal, mp: 137-140 °C (from MeOH). ¹H-NMR (400 MHz, CDCl₃): δ = 5.49 (d, *J* = 0.8 Hz, 2H), 7.10 (d, *J* = 8.4 Hz, 1H), 7.58 (t, *J* = 6.8 Hz, 1H), 7.64 (dd, *J* = 8.6 Hz, *J* = 2.4 Hz, 1H), 7.77 (t, *J* = 5.6 Hz, 1H), 7.82 (d, *J* = 8.0 Hz, 1H), 7.93 (s, 1H), 8.17 (d, *J* = 8.4 Hz, 1H), 8.86 (d, *J* = 2.0 Hz, 1H) ppm. ¹³C-

NMR (100 MHz, CDCl_3): δ = 68.6, 106.0, 118.6, 118.9, 123.9, 127.1, 127.5, 127.9, 129.6, 130.1, 130.2, 131.4, 134.9, 146.5, 148.3, 160.2, 175.1 ppm. Mass: m/z 258 (M^+) (calcd for $\text{C}_{17}\text{H}_{10}\text{N}_2\text{O}$: 258.08). FT-IR (KBr): ν_{max} : 1130 (s), 1235 (s), 2223 (s), 3068 (w) cm^{-1} . Analytically calculated for $\text{C}_{17}\text{H}_{10}\text{N}_2\text{O}$: C 79.06, H 3.90, N, 10.85%. Found: C 78.88; H 3.71; N 10.77%.

2-(tert-Butyl)-6H-chromeno [4, 3-b] quinoline (2g). Yellow needle crystal, mp: 68–71 °C (from MeOH). ^1H -NMR (400 MHz, CDCl_3): δ = 1.46 (s, 9H), 5.36 (d, J = 0.8 Hz, 2H), 7.00 (d, J = 8.8 Hz, 1H), 7.46 (dd, J = 8.6 Hz, J = 2.8 Hz, 1H), 7.52 (t, J = 7.6 Hz, 1H), 7.72 (t, J = 7.6 Hz, 1H), 7.80 (d, J = 8.0 Hz, 1H), 7.89 (s, 1H), 8.19 (d, J = 8.8 Hz, 1H), 8.55 (d, J = 2.4 Hz, 1H) ppm. ^{13}C -NMR (100 MHz, CDCl_3): δ = 31.5, 34.6, 68.4, 114.4, 116.9, 121.4, 121.9, 125.5, 126.2, 126.5, 127.3, 127.4, 127.5, 129.4, 133.3, 136.7, 141.2, 155.4 ppm. Mass: m/z 289 (M^+) (calcd for $\text{C}_{20}\text{H}_{19}\text{NO}$: 289.15). Analytically calculated for $\text{C}_{20}\text{H}_{19}\text{NO}$: C 83.01, H 6.62, N, 4.84%. Found: C 83.15; H 6.77; N 4.77%.

4-Methyl-6H-chromeno [4, 3-b] quinoline (2h). Yellow needle crystal, mp: 102–105 °C (from MeOH). ^1H -NMR (400 MHz, CDCl_3): δ = 2.34 (s, 3H), 5.40 (d, J = 0.8 Hz, 2H), 7.10 (t, J = 7.6 Hz, 1H), 7.27 (d, J = 7.0 Hz, 2H), 7.52 (t, J = 7.4 Hz, 1H), 7.72 (t, J = 7.8 Hz, 1H), 7.80 (d, J = 7.4 Hz, 1H), 7.91 (s, 1H), 8.16 (d, J = 8.4 Hz, 1H), 8.37 (d, J = 8.0 Hz, 1H) ppm. ^{13}C -NMR (100 MHz, CDCl_3): δ = 15.8, 68.3, 121.9, 122.8, 123.2, 125.3, 126.2, 126.6, 127.4, 127.5, 129.4, 130.7, 133.1, 148.4, 149.5, 155.6 ppm. Mass: m/z 246 (M^+) (calcd for $\text{C}_{17}\text{H}_{13}\text{NO}$: 247.29). FT-IR (KBr): ν_{max} : 744 (s), 1019 (m), 1204 (s), 1462 (s), 3049 (w) cm^{-1} . Analytically calculated for $\text{C}_{17}\text{H}_{13}\text{NO}$: C 82.57, H 5.30, N, 5.66%. Found: C 82.41; H 5.17; N 5.51%.

9-Bromo-6H-chromeno [4, 3-b] quinoline (2i). Yellow needle crystal, mp: 118–120 °C (from MeOH). ^1H -NMR (400 MHz, CDCl_3): δ = 5.38 (d, J = 0.8 Hz, 2H), 6.77 (d, J = 8.8 Hz, 1H), 7.00 (d, J = 8.8 Hz, 1H), 7.67 (m, 1H), 7.80 (m, 1H), 7.83 (s, 1H), 8.01 (d, J = 9.2 Hz, 1H), 8.09 (d, J = 8.8 Hz, 1H), 8.46 (d, J = 2.8 Hz, 1H) ppm. ^{13}C -NMR (100 MHz, CDCl_3): δ = 68.3, 116.4, 118.9, 121.1, 124.0, 125.1, 126.1, 127.9, 130.1, 130.7, 131.1, 131.4, 131.8, 133.4, 146.7, 155.8 ppm. FT-IR (KBr): ν_{max} : 650 (w), 1130 (w), 1230 (m), 3020 (w) cm^{-1} . Analytically calculated for $\text{C}_{16}\text{H}_{10}\text{BrNO}$: C 61.56, H 3.23, N, 4.49%. Found: C 61.27; H 3.41; N 4.72%.

9-Chloro-6H-chromeno [4, 3-b] quinoline-2-carbonitrile (2j). Yellow needle crystal, mp: 137–140 °C (from MeOH). ^1H -NMR (400 MHz, CDCl_3): δ = 5.49 (d, J = 0.8 Hz, 2H), 7.11 (d, J = 8.4 Hz, 1H), 7.65 (dd, J = 8.4 Hz, J = 2.0 Hz, 1H), 7.70 (dd, J = 9.2 Hz, J = 2.4 Hz, 1H), 7.81 (d, J = 2.4 Hz, 1H), 7.85 (s, 1H), 8.10 (d, J = 8.8 Hz, 1H), 8.82 (d, J = 2.0 Hz, 1H) ppm. ^{13}C -NMR (100 MHz, CDCl_3): δ = 68.4, 106.2, 118.7, 118.8, 123.5, 124.9, 126.2, 128.4, 130.3, 130.4, 131.1, 131.2, 132.8, 135.2, 146.7, 146.8, 160.2 ppm. Mass: m/z 291 (M^+) (calcd for $\text{C}_{17}\text{H}_9\text{ClN}_2\text{O}$: 292.04). FT-IR (KBr): ν_{max} : 779 (m), 1130 (m), 1235 (s), 3067 (w) cm^{-1} . Analytically calculated for $\text{C}_{17}\text{H}_9\text{ClN}_2\text{O}$: C 69.75, H 3.10, N, 9.57%. Found: C 69.58; H 3.17; N 9.71%.

9-Methyl-6H-chromeno [4, 3-b] quinoline-2-carbonitrile (2k). Colorless needle crystal, mp: 147–150 °C (from MeOH). ^1H -NMR (400 MHz, CDCl_3): δ = 2.58 (s, 3H), 5.47 (d, J = 0.8 Hz, 2H), 7.09 (d, J = 8.4 Hz, 1H), 7.58–7.64 (m, 3H), 7.83 (s, 1H), 8.05 (d, J = 8.4 Hz, 1H), 8.83 (d, J = 2.0 Hz, 1H) ppm. ^{13}C -NMR (100 MHz, CDCl_3): δ = 21.6, 68.6, 106.0, 118.5, 118.9, 123.9, 124.0, 126.4, 127.9, 129.2, 130.1, 130.7, 132.4, 134.7, 137.2, 145.7, 146.9, 160.1 ppm. Mass: m/z 271 (M^+) (calcd for $\text{C}_{18}\text{H}_{12}\text{N}_2\text{O}$: 272.09). FT-IR (KBr): ν_{max} : 1122 (m), 1236 (s), 2233 (s), 2855 (w), 3030 (w) cm^{-1} . Analytically calculated for

$\text{C}_{18}\text{H}_{12}\text{N}_2\text{O}$: C 79.39, H 4.44, N, 10.29%. Found: C 79.47; H 4.62; N 10.51%.

2-Fluoro-9-methyl-6H-chromeno [4, 3-b] quinoline (2l). Yellow needle crystal, mp: 92–95 °C (from MeOH). ^1H -NMR (400 MHz, CDCl_3): δ = 2.57 (s, 3H), 5.36 (d, J = 0.8 Hz, 2H), 7.00 (m, 1H), 7.08 (m, 1H), 7.54–7.58 (m, 2H), 7.83 (s, 1H), 8.06 (d, J = 9.2 Hz, 1H), 8.18 (dd, J = 8.8 Hz, J = 3.2 Hz, 1H) ppm. ^{13}C -NMR (100 MHz, CDCl_3): δ = 21.6, 68.5, 111.3, 111.5, 118.4, 118.5, 118.6, 125.0, 126.3, 127.8, 128.9, 130.6, 132.2, 157.2, 159.6 ppm. Mass: m/z 264 (M^+) (calcd for $\text{C}_{17}\text{H}_{12}\text{FNO}$: 265.09). FT-IR (KBr): ν_{max} : 828 (m), 1118 (m), 1274 (m), 3050 (w) cm^{-1} . Analytically calculated for $\text{C}_{17}\text{H}_{12}\text{FNO}$: C 76.97, H 4.56, F 7.16, N, 5.28%. Found: C 76.82; H 4.65; N 5.41%.

12H-Benzo [5, 6] pyrrolizino [1, 2-b] quinoline (4a). Yellow needle crystal, mp: 128–130 °C (from MeOH). ^1H -NMR (400 MHz, CDCl_3): δ = 5.28 (s, 2H), 7.20 (t, J = 4.0 Hz, 1H), 7.20 (s, 1H), 7.31 (t, J = 7.6 Hz, 1H), 7.45 (d, J = 8.4 Hz, 1H), 7.55 (t, J = 4.0 Hz, 1H), 7.76 (t, J = 8.0 Hz, 1H), 7.81 (d, J = 8.0 Hz, 1H), 7.83 (d, J = 9.2 Hz, 1H), 8.16 (s, 1H), 8.21 (d, J = 8.8 Hz, 1H) ppm. ^{13}C -NMR (100 MHz, CDCl_3): δ = 46.5, 95.3, 109.5, 120.4, 122.8, 123.0, 126.3, 126.6, 127.9, 129.1, 129.8, 130.1, 132.7, 133.6, 134.4, 140.9, 148.5, 153.1 ppm. Mass: m/z 256 (M^+) (calcd for $\text{C}_{18}\text{H}_{12}\text{N}_2$: 256.10). FT-IR (KBr): ν_{max} : 1318 (m), 1570 (m), 2919 (w), 3003 (w) cm^{-1} . Analytically calculated for $\text{C}_{18}\text{H}_{12}\text{N}_2$: C 84.35, H 4.72, N 10.93%. Found: C 84.42; H 4.61; N 10.65%.

8-Chloro-12H-benzo [5, 6] pyrrolizino [1, 2-b] quinoline (4b). Yellow needle crystal, mp: 117–120 °C (from MeOH). ^1H -NMR (400 MHz, CDCl_3): δ = 5.28 (s, 2H), 7.12 (s, 1H), 7.24 (dd, J = 8.6 Hz, J = 2.0 Hz, 1H), 7.36 (d, J = 8.8 Hz, 1H), 7.58 (t, J = 7.6 Hz, 1H), 7.76–7.79 (m, 2H), 7.84 (d, J = 8.4 Hz, 1H), 8.17 (s, 1H), 8.21 (d, J = 8.4 Hz, 1H) ppm. ^{13}C -NMR (100 MHz, CDCl_3): δ = 46.7, 110.5, 122.0, 123.4, 126.2, 126.6, 127.9, 130.0, 130.3, 132.8, 133.4, 133.5, 149.3, 150.8, 153.3, 153.9 ppm. Mass: m/z 290 (M^+) (calcd for $\text{C}_{18}\text{H}_{11}\text{ClN}_2$: 290.06). FT-IR (KBr): ν_{max} : 800 (s), 1380 (m), 1700 (m), 2967 (m) cm^{-1} . Analytically calculated for $\text{C}_{18}\text{H}_{11}\text{ClN}_2$: C 74.36, H 3.81, N 9.64%. Found: C 74.23; H 3.70; N 9.53%.

Acknowledgments

We are thankful to Alzahra University and Iran National Science Foundation (INSF) for financial support.

References and notes

- (a) Yin, L.; Liebscher, J. *Chem. Rev.* **2007**, *107*, 133–137. (b) Alonso, F.; Beletskaya, I. P.; Yus, M. *Tetrahedron* **2005**, *61*, 11771–11835. (c) Biffis, A.; Zecca, M.; Basato, M. *J. Mol. Catal. A Chem.* **2001**, *173*, 249–274.
- (a) Jeffery, T. *J. Chem. Soc., Chem. Commun.* **1984**, 1287–1289. (b) Bankston, D.; Fang, F.; Huie, E.; Xie, S. *J. Org. Chem.* **1999**, *64*, 3461–3466. (c) Jeffery, T. *Synthesis* **1987**, 70–71. (d) Jeffery, T. *Tetrahedron Lett.* **1985**, 26, 2667–2670.
- (a) Beletskaya, I. P.; Cheprakov, A. V. *Chem. Rev.* **2000**, *100*, 3009–3066. (b) Dounay, A. B.; Overman, L. E. *Chem. Rev.* **2003**, *103*, 2945–2964. (c) Shibasaki, M.; Boden, C. D. J.; Kojima, A. *Tetrahedron* **1997**, *53*, 7371–7395.
- Danishefsky, S. J.; Masters, J. J.; Young, W. B.; Link, J. T.; Snyder, L. B.; Magee, T. V.; Jung, D. K.; Isaacs, R. C. A.; Bornmann, W. G.; Alaimo, C. A.; Coburn, C. A.; Di Grandi, M. J. *J. Am. Chem. Soc.* **1996**, *118*, 2843–2859.
- Abbas, S.; Ferris, L.; Norton, A. K.; Powell, L.; Robinson, G. E.; Siedlecki, P.; Southworth, R. J.; Stark, A.; Williams, E. G. *Org. Process Res. Dev.* **2008**, *12*, 202–212.

6. Singh, J. B.; Bharadwaj, K. C.; Gupta, T.; Singh, R. M. *RSC Adv.* **2016**, *6*, 26993-26999.

7. (a) Li, W.; Gao, J. J.; Zhang, Y.; Tang, W.; Lee, H.; Fandrick, K. R.; Lu, B.; Senanayake, C. H. *Adv. Synth. Catal.* **2011**, *353*, 1671-1675. (b) Kleeman, A.; Engel, J.; Kutscher, B.; Reichert, D. *Pharmaceutical Substances. Synthesis, Patents, Applications*, Georg Thieme Verlag, Stuttgart, Germany, 2001.

8. References therein: (a) Natarajan, J. K.; Alumasa, J. N.; Yearick, K.; Ekoue-Kovi, K. A.; Casabianca, L. B.; de Dios, A. C.; Wolf, C.; Roepe, P. D. *J. Med. Chem.* **2008**, *51*, 3466-3479. (b) De, D.; Krogstad, F. M.; Byers, L. D.; Krogstad, D. J. *J. Med. Chem.* **1998**, *41*, 4918-4926. (c) Delarue, S.; Girault, S.; Maes, L.; Debreu-Fontaine, M. A.; Labaeid, M.; Grellier, P.; Sergheraert, C. *J. Med. Chem.* **2001**, *44*, 2827-2833. (d) Stocks, P. A.; Raynes, K. J.; Bray, P. G.; Park, B. K.; O'Neill, P. M.; Ward, S. A. *J. Med. Chem.* **2002**, *45*, 4975-4983. (e) O'Neill, P. M.; Willock, D. J.; Hawley, S. R.; Bray, P. G.; Storr, R. C.; Ward, S. A.; Park, B. K. *J. Med. Chem.* **1997**, *40*, 437-448.

9. (a) Vu, A. T.; Campbell, A. N.; Harris, H. A.; Unwalla, R. J.; Manasc, E. S.; Mewshaw, R. E. *Bioorg. Med. Chem. Lett.* **2007**, 4053-4056. (b) Vu, A. T.; Cohn, S. T.; Manas, E. S.; Harris, H. A.; Mewshaw, R. E. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 4520-4525.

10. Hegab, M. I.; Abdel-Fattah, A. M.; Yousef, N. M.; Nour, H. F.; Mostafa, A. M.; Ellithey, M. *Arch. Pharm. Chem. Life Sci.* **2007**, *340*, 396-403.

11. (a) Sabitha, G.; Satheesh Babu, R.; Subba Reddy, B. V.; Yadav, J. S. *Synth. Commun.* **1999**, *29*, 4403-4408. (b) Rougeot, P. E.; Moskowitz, H.; Miocque, M. *Tetrahedron Lett.* **1983**, *24*, 2379-2382. (c) Ramesh, S.; Gaddam, V.; Nagarajan, R. *Synlett* **2010**, 757-760. (d) Ibrahim, Y. A.; Moustafa, A. H. *J. Chem. Res. (M)* **1999**, *4*, 1231-1239.

12. Yu, X.; Wang, J.; Xu, Z.; Yamamoto, Y.; Bao, M. *Org. Lett.* **2016**, *18*, 2491-2494.

13. Aradi, K.; Bombicz, P.; Novk, Z. *J. Org. Chem.* **2016**, *81*, 920-931.

14. (a) Faghihi, Z.; Oskooie, H. A.; Heravi, M. M.; Tajbakhsh, M.; Shiri, M. *Monatsh Chem.* **2016**. (b) Shiri, M.; Faghihi, Z.; Oskoei, H. A.; Heravi, M. M.; Fazelzadeh, S.; Notashb, B. *RSC Adv.* **2016**, *6*, 92235-92240. (c) Shiri, M.; Zolfigol, M. A.; G. H.; Kruger, Tanbakouchian, Z. Friedländer annulation in the synthesis of azaheterocyclic compounds in the *Advances in Heterocyclic Chemistry*, A. R. Katritzky, Ed.; Elsevier Science, **2011**, Vol. 102, pp. 139-227. (d) Shiri, M.; Pourabed, R.; Zadsirjan, V.; Sodagar, E. *Tetrahedron Lett.* **2016**, *57*, 5435-5438. (e) Shiri, M.; Zolfigol, M. A.; Pirveysian, M.; Ayazi-Nasrabadi, R.; Kruger, H. G.; Naicker, T.; Mohammadpoor-Baltork, I. *Tetrahedron*, **2012**, *68*, 6059-6064.

15. (a) Wang, G.-B.; Wang, L.-F.; Li, C.-Z.; Sun, J.; Zhou, G.-M.; Yang, D.-C. *Res. Chem. Intermed.* **2012**, *38*, 77-89. (b) Baruah, B.; Bhuyan, P. J. *Tetrahedron* **2009**, *65*, 7099-7104. (c) Kumar, S.; Bawa, S.; Drabu, S.; Panda, B. P. *Med. Chem. Res.* **2011**, *20*, 1340-1348. (d) Jawale, D. V.; Pratap, U. R.; Mane, R. A. *Bull. Korean Chem. Soc.* **2011**, *32*, 2171-2177.

Graphical Abstract

Novel Strategy for Synthesis of 6*H*-chromeno[4,3-*b*] Quinolone by Intramolecular Heck Cyclization

Morteza Shiri*, Mina Fathollahi-Lahroud, Zahra Yasaei

Department of Chemistry, Alzahra University, Vanak, Tehran

Leave this area blank for abstract info.